文献速递真菌感染

CD19嵌合抗原受体T细胞治疗后毛霉病:美国食品药品监督管理局不良事件报告系统分析及文献综述

Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature.
PubMed 文献 · Lancet Infect Dis · 2024-02-01

本文报告一例54岁接受CAR T细胞治疗的患者发生毛霉病,经积极手术清创、抗真菌药物及逆转危险因素后达到临床完全控制,但广泛口面部手术导致言语和吞咽显著并发症。结合FDA不良事件报告数据库分析和文献综述,评估CAR T细胞治疗患者毛霉病的临床负担,讨论流行病学、临床特征、诊断工具及治疗预防框架。

要点

  • CAR T细胞治疗相关免疫抑制可致非典型感染,毛霉病在血液恶性肿瘤患者中死亡风险达40-80%。
  • 早期启动治疗对有效管理毛霉病至关重要,需提高CAR T细胞治疗医生和微生物学家的警惕性。
  • 对最高风险患者进行靶向监测和霉菌预防,以及毛霉目特异性筛查试验,可能改善预后。

核心结论

  • 毛霉病是CAR T细胞治疗后侵袭性真菌感染,死亡风险高,早期诊断和治疗对改善预后关键。

研究设计与样本

  • Grand Round形式,报告一例54岁接受CAR T细胞治疗发生毛霉病的病例,并结合美国食品药品监督管理局不良事件报告数据库分析及文献综述。

主要发现

  • 54岁患者经积极手术清创、抗真菌药物及逆转危险因素后达到毛霉目临床完全控制,但广泛口面部手术导致言语和吞咽显著并发症。
  • 毛霉病在血液恶性肿瘤患者中死亡风险为40-80%。

临床怎么用

  • 作者建议提高CAR T细胞治疗专科医生和微生物学家对毛霉病的警惕性,并强调早期启动治疗以有效管理该病。
  • 作者认为对最高风险患者进行靶向监测和霉菌预防,以及毛霉目特异性筛查试验,可能对改善接受CAR T细胞治疗患者的预后至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy leads to durable remissions in relapsed B-cell cancers, but treatment-associated immunocompromise leads to a substantial morbidity and mortality risk from atypical infection. Mucormycosis is an aggressive and invasive fungal infection with a mortality risk of 40-80% in patients with haematological malignancies. In this Grand Round, we report a case of mucormycosis in a 54-year-old patient undergoing CAR T-cell therapy who reached complete clinical control of Mucorales with combined aggressive surgical debridement, antifungal pharmacotherapy, and reversal of underlying risk factors, but with substantial morbidity from extensive oro-facial surgery affecting the patient's speech and swallowing. For broader context, we present our case alongside an US Food and Drugs Administration adverse events reporting database analysis and a review of the literature to fully evaluate the clinical burden of mucormycosis in patients treated with CAR T-cell therapy. We discuss epidemiology, clinical features, diagnostic tools, and current frameworks for treatment and prophylaxis. We did this analysis to promote increased vigilance for mucormycosis among physicians specialising in CAR T-cell therapy and microbiologists and to illustrate the importance of early initiation of therapy to effectively manage this condition. Mucormycosis prevention and early diagnosis, through targeted surveillance and mould prevention in patients at highest risk and Mucorales-specific screening assays, is likely to be key to improving outcomes in patients treated with CAR T-cell therapy.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cheok KPL, Farrow A, Springell D, et al. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature. Lancet Infect Dis. 2024. PMID: 38310904. doi:10.1016/S1473-3099(23)00563-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。